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To elucidate further the role, in normal development and in disease pathogenesis, of TFAP2B, a transcription factor
expressed in neuroectoderm, we studied eight patients with Char syndrome and their families. Four novel mutations
were identified, three residing in the basic domain, which is responsible for DNA binding, and a fourth affecting
a conserved PY motif in the transactivation domain. Functional analyses of the four mutants disclosed that two,
R225C and R225S, failed to bind target sequence in vitro and that all four had dominant negative effects when
expressed in eukaryotic cells. Our present findings, combined with data about two previously identified TFAP2B
mutations, show that dominant negative effects consistently appear to be involved in the etiology of Char syndrome.
Affected individuals in the family with the PY motif mutation, P62R, had a high prevalence of patent ductus
arteriosus but had only mild abnormalities of facial features and no apparent hand anomalies, a phenotype different
from that associated with the five basic domain mutations. This genotype-phenotype correlation supports the
existence of TFAP2 coactivators that have tissue specificity and are important for ductal development but less
critical for craniofacial and limb development.
Introduction
Char syndrome (MIM 169100) is an autosomal domi-
nant disorder characterized by patent ductus arteriosus
(PDA), facial dysmorphism, and abnormalities of the
fifth finger (Char 1978). In studies reported elsewhere,
our group linked Char syndrome to chromosome 6p12-
p21.1, using two large kindreds with this disorder (Sa-
toda et al. 1999), and then identified disease-causing
mutations in the transcription factor TFAP2B (also
known as AP-2b [MIM 601601]) from one of those
families, as well as from a second, smaller kindred (Sa-
toda et al. 2000).
The TFAP2 transcription factors constitute a family
of closely related and evolutionarily conserved se-
quence-specific DNA-binding proteins. TFAP2 genes
have been identified in an invertebrate (Drosophila mel-
anogaster) and several vertebrates, including Xenopus
laevis, chickens, mice, and humans (Williams et al.
1988; Winning et al. 1991; Moser et al. 1995; Chazaud
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et al. 1996; Williamson et al. 1996; Shen et al. 1997;
Bauer et al. 1998). Although the Drosophila genome
contains a single TFAP2 gene, there have been evolu-
tionary duplications, such that mice and humans have
at least three TFAP2 genes. The three murine Tfap2
genes (Tfap2a, Tfap2b, and Tfap2c) are expressed in
the developing limbs, epithelia, and neuroectoderm, in-
cluding neural crest–derived tissues, such as the facial
mesenchyme (Mitchell et al. 1991; Moser et al. 1995,
1997b). TFAP2 proteins form homo- and heterodimers
with other TFAP2 family members. Dimers bind to pal-
indromic GC-rich DNA-binding sequences in promoter
regions of certain genes, activating their transcription.
In addition to the observation that TFAP2B defects
cause Char syndrome, TFAP2 gene defects have been
associated with developmental anomalies in flies and
mice. In Drosophila, several dAP-2 mutants were iden-
tified through a mutagenesis screen (Monge et al. 2001).
Null mutations resulted in reduced proboscis, shortened
legs, and brain abnormalities; hypomorphic alleles
caused more-modest changes in leg length. Mice with
targeted disruptions of Tfap2a (MIM 107580) and
Tfap2b (MIM 601602) have strikingly different phe-
notypes (Schorle et al. 1996; Zhang et al. 1996; Moser
et al. 1997a), establishing that the roles of these Tfap2
genes are not redundant. Tfap2a-deficient mice have
severe and diffuse anomalies, including anencephaly,
body-wall defects, and craniofacial defects (Schorle et
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Figure 1 Clustal W alignment of human TFAP2 protein se-
quences. A, Alignment of the basic domains of the TFAP2 proteins.
Numbering is according to the TFAP2B amino acid sequence. Identical
amino acid residues are shaded in gray. The three novel and two pre-
viously reported mutations are indicated. B, Alignment of a portion
of the transactivation domains that includes the PY motif. The P62R
mutation is indicated.
al. 1996; Zhang et al. 1996). Loss of Tfap2b causes
congenital polycystic kidney disease due to excessive
apoptosis of renal epithelial cells (Moser et al. 1997a),
a phenotype strikingly different from Char syndrome.
Potential adverse effects of missense defects in TFAP2
genes can often be predicted on the basis of position,
because the three functional domains that constitute the
polypeptide have a completely conserved arrangement
among all TFAP2 family members. The N-terminal por-
tion of the protein contains the transactivation domain,
which has an amino acid sequence that is relatively
poorly conserved among the TFAP2 proteins. The basic
and helix-span-helix (HSH) domains constitute the C-
terminal half of the protein and are highly conserved
among all TFAP2 orthologues and paralogues. The ba-
sic domain is necessary for DNA binding, and the HSH
domain has DNA binding and dimerization functions
(Williams and Tjian 1991). The two TFAP2B gene de-
fects previously identified in families of patients with
Char syndrome were missense mutations affecting the
basic domain (Satoda et al. 2000). Functional analyses
of these mutants disclosed that both prevent binding to
TFAP2 target sequence and act in a dominant negative
manner.
The purpose of the present study was to document
the degree of molecular heterogeneity of TFAP2B
mutations underlying Char syndrome, to determine
whether disease-causing mutants acted consistently in a
dominant negative manner and to correlate genotype
with phenotype. Four novel TFAP2B mutations were
identified among eight unrelated patients with Char syn-
drome and their families. Three missense mutations, ob-
served in patients with the classic phenotype, altered
highly conserved residues in the basic domain and had
dominant negative effects. A family with high preva-
lence of PDA, mild facial anomalies, and normal hands
was found to be inheriting a missensemutation affecting
the conserved PY motif in the transactivation domain.
This mutant bound target sequence in a normal manner
but had dominant negative effects on transactivation.
These data, combined with information about the two
previously identified mutations, suggest that dominant
negative effects, generally involving basic domain al-
terations, are necessary for the pathogenesis of Char
syndrome. The genotype-phenotype correlation ob-
served with the transactivation domain mutant suggests
that ductal development depends critically on interac-
tions of TFAP2B with one or more TFAP2 coactivators,




Blood samples were obtained, with informed consent,
from eight unrelated families with one or more individ-
uals affected with Char syndrome. Genomic DNA was
extracted from blood leukocytes, using the Puregene
Genomic DNA Isolation kit. Sense and antisense oligo-
nucleotide primers that correspond to intronic sequences
flanking the TFAP2B coding exons were used to amplify
those exons and their intronic junctions from genomic
DNAs. Amplified DNA products were sequenced bi-
directionally on an ABI 3700 DNA sequencer by cycle
sequencing.
To confirm the changes identified, PCR-based muta-
tion assays were developed. The P62R mutation intro-
duced a FauI site, and the two R225 mutations oblit-
erated a HaeIII site, facilitating these analyses. For the
R274Q mutation, a mismatch primer that introduced an
HhaI site in the wild-type amplimer, but not the mutant,
was used. For all assays, PCR products were digested
with the appropriate restriction endonuclease and were
visualized directly with ethidium bromide after electro-
phoresis on a 2% horizontal agarose gel. More than 50
control individuals were examined for the presence of
these changes, using these mutation assays.
In Vitro Transcription and Translation
Clones containing the human TFAP2B and TFAP2A
cDNAs were provided by H. Hurst and T. Williams,
respectively. To create mutant constructs, site-directed
mutagenesis was performed using the PCR ligation
method with Pfu Taq polymerase (Stratagene). After li-
gation into pSP64 Poly(A) (Promega) and sequence con-
firmation, in vitro transcription and translation were
performed using the TnT Quick Coupled Transcription/
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Translation System (Promega), according to the manu-
facturer’s protocol. These proteins, which were labeled
by incorporation of [35S]-methionine, were separated by
SDS-PAGE and detected by use of autoradiography.
Electromobility Shift Assays (EMSAs)
TFAP2 proteins were used in EMSAs with the
MT2A 180 TFAP2 binding sequence (5′-GAACTG-
ACCGCCCGCGGCCCGTGTGCAGAG-3′) (Promega)
that had been end-labeled with 32P, using the T4 poly-
nucleotide kinase. DNA-protein binding was per-
formed at room temperature, for 30 min, in a reaction
mixture that contained 3 ml of reticulocyte lysate,
0.07 pmol 32P-labeled oligonucleotide, 4% glycerol,
1.2 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50
mM NaCl, 10 mM Tris HCl (pH 7.5), and 0.05 mg/ml
poly(dI-dC)7poly(dI-dC). The products were fraction-
ated on a 4% nondenaturing polyacrylamide gel at 4C.
Gels were dried and exposed through two blank films
to attenuate the 35S signal. Similar EMSAs were carried
out with mutant and wild-type TFAP2B proteins that
had been cotranslated with a truncated TFAP2A
(DN165) that retained DNA binding and dimerization
properties (kindly provided by T. Williams).
Cross-Linking
Ethylene glycol bis(succinimidylsuccinate) (EGS) (Sig-
ma) was dissolved in DMSO just before use. It was in-
cubated, at room temperature, at a final concentration
of 8 mM, together with 2 ml of the reticulocyte lysate
in a reaction mixture that contained 67 mM triethan-
olamine (pH 8.0), 1.3 mM EDTA, 3.3 mM glycerol, and
19 mM b-mercaptoethanol. After 30 min, the reaction
was stopped by adding lysine to a final concentration
of 77 mM. Samples were boiled briefly in SDS sample
buffer containing 1% DTT and 25 mM b-mercapto-
ethanol and were then separated on a 10% gel for SDS-
PAGE. Signals were detected by autoradiography.
Transfections and Chloramphenicol Acetyl Transferase
Assays
The eukaryotic expression vector pSP72RSV, which
contained wild-type TFAP2B, and the chloramphenicol
acetyl transferase (CAT) reporter constructs, with and
without the TFAP2 binding sequences (A2BCAT and
BCAT, respectively), were provided by T. Williams. Mu-
tant TFAP2B cDNAs were shuttled into pSP72RSV, and
the POLR2TC1 cDNA (previously known as “PC4”;
provided by M. Tainsky) (Kannan and Tainsky 1999)
was transferred into the eukaryotic expression vector
pcDNA3.1 (Invitrogen). NIH3T3 cells (American Type
Culture Collection) were incubated at 37C and 5%CO2
in Dulbecco’s minimal essential medium (Sigma), sup-
plemented with 10% fetal calf serum (Gibco). Using
Lipofectamine (Gibco), we transfected the cells with the
DNA constructs, which were then expressed transiently.
For all conditions, total transfected DNA was held con-
stant, using an unrelated plasmid as needed.
After 60 h, the transfected cells were lysed, and relative
CAT concentrations were determined in duplicate by
CAT enzyme-linked immunosorbent assay (Boehringer).
To normalize for transfection efficiency and cell number,
a green fluorescent protein (GFP) reporter construct
(pQBI25; QBI) was cotransfected, and GFP concentra-
tions were measured in the cell lysates with a FOCI Sys-
tem 3 spectrofluorometer. Normalized CAT levels in cells
transfected with A2BCAT alone were arbitrarily set at
1. All transfection conditions were repeated a minimum
of three times. Mean normalized CAT levels were com-
pared using the Student’s t test with the significance
threshold set at .P ! .01
Results
TFAP2B Mutations
The coding TFAP2B exons and their intronic bound-
aries were amplified and sequenced bidirectionally from
eight patients with Char syndrome and their families.
Among this cohort, missense mutations were identified
in four individuals.
A Palestinian boy with PDA, clinodactyly, facial fea-
tures typical of Char syndrome, and a supernumerary
nipple was recruited. Interestingly, his parents were first
cousins, and a male first cousin, whose parents were also
consanguineous, was found to have a PDA but no other
features of Char syndrome. Analysis of the proband’s
DNA identified a coding region alteration in exon 4, a
CrT transition at nucleotide (nt) 673 of the TFAP2B
cDNA, which was present in heterozygosity. This se-
quence change predicted a substitution of an arginine
by a cysteine at position 225 (R225C) in the TFAP2B
basic domain. Because this alteration obliterated a
HaeIII site, it was readily assayed for in DNA fragments
amplified from the proband’s parents’ and cousin’s DNA
samples. RFLP analysis revealed that neither the pro-
band’s parents nor his cousin harbored the R225C
change. Analysis of 1100 Israeli Arab control chromo-
somes failed to reveal this alteration. Comparison of the
three human TFAP2 transcription factors (fig. 1A), as
well as the other vertebrate and invertebrate proteins
(data not shown), revealed that Arg225 is completely
conserved.
An English family that has been described elsewhere
(Sweeney et al. 2000) and that had typical facial features
and hand anomalies, but no cardiovascular abnormal-
ities, was also found to have an exon 4 mutation at nt
673. This change was a CrA transversion that was pre-
dicted to replace Arg225 with a serine residue (R225S).
Using the same HaeIII RFLP employed for the R225C
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Figure 2 Expression and function of recombinant TFAP2B proteins. Left, Autoradiogram of an SDS-PAGE with expressed wild-type (wt)
and mutant TFAP2B proteins. Mobility of proteins of varying mass are indicated at the right. Right, Autoradiogram of an EMSA performed
using the recombinant TFAP2B proteins that had been incubated with [32P]-labeled DNA with the consensus TFAP2 binding sequence. Free
probe is indicated at bottom.
Figure 3 EMSA with cotranslated TFAP2B and truncated
TFAP2A proteins. Truncated TFAP2A (DN165), which retains di-
merization and DNA-binding properties, was cotranslated with
wild-type and mutant TFAP2B. TFAP2 proteins were incubated
with [32P]-labeled DNA with the consensus TFAP2 binding se-
quence and electrophoresed. The two homodimer species (upper
and lower shifted complexes) and the heterodimer (intermediate
shifted complex) are indicated.
mutation, we confirmed that this R225S mutation was
present in available affected individuals and was absent
in 1100 control chromosomes from white Americans.
An Australian family with four affected individuals
was analyzed. All patients had a similar markedly anom-
alous facial appearance and PDA, but no hand anom-
alies were noted. A GrA transition at nt 821 in exon 5
was identified, which was predicted to change an argi-
nine to a glutamine at position 274 (R274Q). Because
this change neither created nor destroyed a restriction
site, mismatch PCR was used to introduce an HhaI site
in amplimers with the wild-type sequence. With the use
of this assay, the R274Q change was confirmed in af-
fected family members and excluded from white control
individuals. Like Arg225, Arg274 resides within the basic
domain and is completely conserved among all verte-
brate and invertebrate TFAP2 proteins (fig. 1A).
The fourth family found to have a TFAP2B mutation
was a large kindred from Minnesota that has been de-
scribed elsewhere (Sletten and Pierpont 1995) andwhose
disease was independently linked to 6p12-p21.1 in a
genome scan (Satoda et al. 1999). The phenotype in this
family is notable for a high prevalence of PDA (10 [71%]
of 14 affected individuals), mildly anomalous facial fea-
tures, and normal hands. In addition, one affected in-
dividual had a muscular ventricular septal defect when
examined at age 8.5 years, and another died of complex
cyanotic heart disease in adulthood. Analysis of exon 2
revealed a CrG transversion at nt 185, which was pre-
dicted to replace a proline with an arginine (P62R). This
mutation introduced a FauI site that facilitated the assay
for this gene defect. Analysis of this family revealed that
the P62R mutation was present in all available affected
individuals but not in unaffected family members or
white control individuals. Pro62 resides in the transac-
tivation domain, a region that is less well conserved
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Figure 4 Chemical cross-linking of recombinant TFAP2B pro-
teins. Autoradiography of wild-type and R225C TFAP2B proteins that
were translated in vitro with incorporation of 35S-Met, and then elec-
trophoresed, under denaturing conditions, after a 30-min exposure to
the chemical cross-linker EGS () or without exposure (). Mobility
of proteins of varying mass is indicated at the right. The expected 50-
and 100-kDa masses for the TFAP2B monomers and dimers, respec-
tively, are indicated (left). Untreated R225C protein (shown in left
panel of fig. 2) had the same mass as the monomeric wild-type protein.
among the TFAP2 proteins. This proline residue, how-
ever, lies in a PY motif (Y58F59P60P61P62Y63); P62 is com-
pletely conserved among the TFAP2 proteins, and the
entire motif is highly conserved (fig. 1B). Moreover, al-
teration of this motif (P60A in the context of human
TFAP2A) has been shown to have adverse effects on
transactivation activity (Wankhade et al. 2000).
Functional Assays of Mutant TFAP2B Binding
EMSAs were used to assess the ability of mutant
TFAP2B proteins to bind TFAP2 target DNA sequence.
Wild-type and mutant proteins were translated in vitro
(fig. 2A) and incubated with the palindromic TFAP2
recognition sequence from position 180 of the human
metallothionein-2A gene (MT2A-180). The wild-type
TFAP2B produced protein-DNA complexes with re-
tarded mobility (fig. 2B). As anticipated on the basis of
the position of the mutation, P62R protein also shifted
probe normally. The R274Q mutant weakly shifted a
complex, a finding that was reproducible. The two R225
mutants did not engender shifts. Since the three mutant
TFAP2B proteins with abnormal EMSA results harbored
changes in the basic domain, it was likely that their
dysfunction arose from a failure to bind target DNA
sequence.
Next, wild-type and mutant TFAP2B genes were co-
translated with a truncated TFAP2A, DN165, which re-
tains the ability to dimerize and bind DNA. Cotransla-
tion of the two genes results in three protein species
(TFAP2B homodimers, DN165 homodimers, and
TFAP2B-DN165 heterodimers) that can be separated in
an EMSA because of differences in mass. When the wild-
type TFAP2B was used, the three shifted complexes were
observed (fig. 3). As expected from the previous EMSAs,
the P62R and R274Q cotranslation lysates also pro-
duced the three shifted complexes. Using the R225S co-
translation products, we noted two shifted species that
corresponded to the DN165 homodimers and the
R225S-DN165 heterodimers. This result documented
that R225S protein was capable of dimerizing and did
not have strong dominant negative effects in vitro. Sim-
ilar analysis with the R225C mutant revealed only a
single shifted complex, which corresponded to the
DN165 homodimers. This experiment did not permit us
to determine whether the R225C protein was failing to
dimerize or was not binding target DNA, although we
suspect the latter was true.
Cross-Linking
To determine formally whether the R225C protein
dimerized, chemical cross-linking of wild-type and
R225C mutant TFAP2B proteins was performed using
the chemical cross-linker EGS. After electrophoresis of
the cross-linked proteins on a denaturing gel, TFAP2B
monomers with a mass of ∼50 kDa were observed in
all lanes, whereas dimers of ∼100 kDa were visible only
for the EGS-treated proteins (fig. 4). These results doc-
umented that R225C mutant protein was able to di-
merize, establishing that it failed to bind TFAP2 target
sequence per se. When this failure is combined with the
EMSA data, it strongly supports the conclusion that
R225C protein had strong dominant negative effects in
vitro.
Transactivation in Eukaryotic Cells
To assess the ability of the mutant TFAP2B proteins
to transactivate gene expression, eukaryotic expression
constructs with the mutant genes were cotransfected into
NIH3T3 cells along with a CAT reporter construct con-
taining three copies of the TFAP2-binding site MT2A
180 (A2BCAT). As in work we reported elsewhere
(Satoda et al. 2000), the TFAP2 coactivator,POLR2TC1
(also known as PC4), was cotransfected to prevent tran-
scription self-interference.
NIH3T3 cells had a low level of endogenous TFAP2
activity, as demonstrated by the small difference in CAT
concentrations that depends on the presence or absence
of TFAP2 binding sites in the reporter construct
(A2BCAT vs. BCAT, respectively; ) (fig. 5). Ex-P ! .01
pression of wild-type TFAP2B resulted in a 5.4-fold in-
crease of CAT concentration above the A2BCAT-only
baseline. All four TFAP2B mutants produced CAT levels
that were significantly less than those obtained with
wild-type TFAP2B ( ). For the P62R mutant, CATP ! .01
levels were modestly higher than the A2BCAT-only base-
line ( ). On the basis of the EMSA results, weP ! .03
believe this transactivation could be attributable to mu-
tant homodimers or heterodimers formed with endog-
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Figure 5 Transient expression of wild-type or mutant TFAP2B in NIH3T3 cells. Cells were transfected with 1.5 mg of the CAT reporter
construct (A2BCAT) with three copies of TFAP2 binding sequence or an equivalent amount of the CAT-only construct (BCAT). To test for
transactivation, 0.3 mg wild-type (wt) or mutant TFAP2B construct was cotransfected with A2BCAT. After 48 h, cells were lysed, and the CAT
concentrations in the lysates were determined. To normalize for transfection efficiency, 0.5mg of pQB125was cotransfected, andGFPfluorescence
was measured. The bars indicate the mean and standard errors from three independent transfections. Units are arbitrary, and the mean from
the condition with only A2BCAT was set at 1.0.
enous TFAP2 proteins or both. The two R225 mutants
decreased CAT levels below that obtained with A2BCAT
alone ( for both), suggesting interference withP ! .02
endogenous TFAP2 activity. Furthermore, CAT levels
produced by the two R225 mutants were significantly
lower than those obtained with the P62R and R274Q
mutants ( ).P ! .02
To delineate further the effects of the TFAP2Bmutants
on wild-type TFAP2 proteins, mutant and wild-type
TFAP2B constructs were cotransfected. Coexpression of
each of the four mutants with wild-type TFAP2B pro-
duced significantly lower CAT levels than those obtained
from wild-type TFAP2B alone ( ), despite the factP ! .01
that an equal amount of the wild-type construct was
used in all conditions (fig. 6). Because transcription self-
interference does not cause this reduction under these
conditions (Satoda et al. 2000), these results documented
that all four mutants have dominant negative effects.
Differences among the four mutants were noted in
the results of the cotransfection studies. As expected
on the basis of the EMSA data showing that R225C
mutant protein failed to bind target sequence as either
a homodimer or heterodimer, coexpression of R225C
with wild-type TFAP2B produced the lowest CAT levels.
These levels were significantly lower than those obtained
with P62R ( ) or R274Q ( ) but did notP ! .004 P ! .04
reach significance when compared with R225S (P !
). These results were compatible with findings re-.08
cently reported about a Drosophila dAP-2 mutation,
R243C, which altered the corresponding arginine resi-
due (Monge et al. 2001). Flies with R243C in hemi-
zygosity had a severe phenotype comparable to that
associated with mutants that are negative for cross-re-
acting immunological material. When paired with hy-
pomorphic mutations, the R243C mutation caused a
more-severe phenotype, evidence of a dominant negative
effect. Because the Drosophila genome contains a single
TFAP2 gene, these data provide clear confirmation of
the functional effects of R225C protein.
CAT levels that were obtained after coexpression
of R225S and wild-type TFAP2B were similar to those
from R225C and significantly lower than those from
P62R or R274Q coexpression ( ). This resultP ! .05
suggested that R225S wild-type heterodimers were
not binding TFAP2 target sequence well in the milieu
of the cell, even though they bound target under
EMSA conditions. This conclusion is consistent with
the demonstration that R225S expression interfered
with endogenous TFAP2 activity in NIH3T3 cells in
the single-transfection experiment.
Coexpression of P62R and R274Q mutant proteins
with wild-type TFAP2B produced roughly equal CAT
concentrations. Because R274Q homodimers bound tar-
get sequence very poorly in vitro, the major source of
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Figure 6 Transient coexpression of wild and mutant TFAP2B genes in NIH3T3 cells. Cotransfections and analysis were performed as
described in figure 5. Total DNA used during the transfection was made equivalent for all conditions with an unrelated plasmid.
the increase in transactivation relative to the R225 mu-
tants can be attributed to R274Q wild-type heterodi-
mers. It can also be inferred that the P62R homodimers
have little or no capacity to transactivate gene expres-
sion, a result confirming the importance of the PY motif
(Wankhade et al. 2000).
Discussion
Six TFAP2B mutations that cause Char syndrome have
now been identified among 10 patients with the disorder
and their families. Several features are noteworthy. All
disease-causing mutations are missense changes, and the
proteins they encode have consistently dominant nega-
tive effects. This is strikingly different from the proto-
typical heart-hand syndrome, Holt-Oram, for which the
molecular lesions to the transcription factor TBX5 in-
clude missense, nonsense, and frameshift changes and
can have dominant negative or haploinsufficient effects
(Basson et al. 1999). We previously noted that the dis-
crepancy in the phenotypes between patients with Char
syndrome and mice lacking Tfap2b may be attributable
to the difference in the nature of the alleles or to the
variations in roles of the mouse and human TFAP2B
genes during development (Satoda et al. 2000). The ab-
sence of haploinsufficient alleles among the enlarged co-
hort of patients in the present study provides evidence
supporting the former explanation.
Although the entire TFAP2B coding region and the
relevant intron boundaries were scanned for mutations
by use of bidirectional sequencing, only 50% of patients
and families in the present study (60% overall) had
documented defects. This study did not exclude the pos-
sibility that defects in the upstream (and uncharacteri-
zed) regulatory region of the TFAP2B gene or in critical
enhancer elements might produce the Char syndrome
phenotype. Intragenic deletions also were not thor-
oughly excluded. Heterozygosity for TFAP2B intronic
polymorphisms, excluding deletion of the entire gene,
was noted for three of the four individuals without
TFAP2B mutations. These two types of mutations,
which would cause haploinsufficiency, seem unlikely,
because a dominant negative effect would appear to be
required for the pathogenesis of Char syndrome. An
alternative possibility, genetic heterogeneity, could not
be established with the available TFAP2B muta-
tion–negative group but should be examined if an ap-
propriate family with Char syndrome can be identified.
Candidate genes would include other members of the
TFAP2 family and genes whose products are in the same
developmental pathway as TFAP2B. That pathway has
not been well established, although recent work with
Drosophila documented that dAP-2 was downstream
of Notch during leg development (Kerber et al. 2001).
Another striking finding was that four of the six mis-
sense TFAP2B mutations altered arginine residues, but
this amino acid constituted only 5.8% of the protein
and 12.8% of the basic domain. Two putative causes
of this apparently nonrandom mutation pattern seem
plausible. First, arginine residues can be encoded in six
ways, four CGX and two AGR codons. Since the mu-
tation rate at CpG dinucleotides is higher than other
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combinations (Holliday and Grigg 1993), we would ex-
pect a disproportionately high rate of missense muta-
tions to affect arginine codons. In fact, all arginine res-
idues altered in the four TFAP2Bmutations are encoded
by CGX codons. Since CGX codons encode the ex-
pected two thirds of all arginines in TFAP2B, these find-
ings are compatible with the higher mutability mecha-
nism. Second, arginine residues are known to play
critical roles in the binding of transcription factors to
their target sequences (Pabo and Sauer 1992). Specifi-
cally, they can form hydrogen bonds with bases, as well
as with phosphate groups in the DNA backbone. The
latter explanation seemed plausible, because all of the
arginine mutations to TFAP2B resided in the DNA-
binding domain. Moreover, four missense changes to
Arg225 or to its corresponding residue in Drosophila
have been identified (R225C and R225S in humans;
R243C and R243H in flies). All lack DNA-binding ac-
tivity as homodimers and have dominant negative ef-
fects, suggesting that this arginine residue plays a critical
role in DNA binding.
To compare the relative importance of the two mech-
anisms that may underlie the overrepresentation of
arginine point mutations, we reviewed databases for
CFTR and p53, mutations of which cause cystic fibrosis
and Li-Fraumeni syndrome, respectively. These two were
selected, because the former gene encodes a structural
protein and the latter encodes a transcription factor and
because these mutation databases were extensive.
Among 595 CFTR point mutations altering the coding
region, 58 (9.8%; 95% confidence interval [CI] 7.5%–
12.4%) altered arginine residues. Arginine residueswere
disproportionately represented, given that they consti-
tute only 5.3% of the CFTR protein. In contrast, 27 of
116 p53 point mutations (23.3%; 95% CI 15.9%–
32.0%) altered arginine residues, despite the fact that
the arginine content of the protein (5.1%) was nearly
identical to that of CFTR. This could not be attributed
to a skew in codon usage in p53, because 21 of 27
arginine residues were encoded by CGX codons. In ad-
dition, the distribution of the p53 arginine residues that
were mutated appeared to be nonrandom. The DNA-
binding region of p53 contains 18 of the 27 arginine
residues in the protein but harbored 18 of 21 missense
arginine mutations. This propensity to arginine muta-
tions in the DNA-binding domain did not appear to be
related merely to the alteration in charge. Seven lysine
residues are present in the DNA-binding domain of p53,
but only a single lysine missense mutation was reported.
Thus, it appears that the disproportion of arginine mis-
sense mutations observed in TFAP2B and other tran-
scription factors (Basson et al. 1999) can be attributed
to synergism between fundamental genetic and struc-
tural mechanisms.
In the present study, a single missense mutation was
identified that affected a residue in the transactivation
domain. Functional analyses of this mutant, P62R, re-
vealed that it binds DNA normally as a homo- and
heterodimer, but it fails to transactivate as a homodimer
and modestly interferes with transactivation from het-
erodimeric partners. These results confirmed the work
of Wankhade and colleagues, who demonstrated that
mutations of the conserved PY motif, in which Pro62
resides, have dramatic adverse effects on transactiva-
tion (Wankhade et al. 2000). Although the functional
profile of P62R was similar to that of R274Q in the
present study and to that of R289C in our previous
work, the phenotype associated with P62R was strik-
ingly different. The facial phenotype originally de-
scribed by Florence Char has been consistent among
affected individuals, with relatively little intra- or in-
terfamilial variation. In the family bearing the P62R
mutation, the facial dysmorphism was consistently
much milder—so much so that, in the original assign-
ments in that kindred, some individuals who did not
have PDA were mistakenly thought to be unaffected. In
addition, other families with multiple affected individ-
uals have revealed some persons with abnormalities of
the hands, abnormalities that range from aplasia of the
middle phalanx of the fifth digit to clinodactyly. None
of the 14 affected members of the family with the P62R
mutation had such hand defects. Despite the mild facial
and hand phenotype, the prevalence of PDA and other
cardiovascular defects in this family was high. This dis-
crepancy between the effects of P62R on cardiac de-
velopment versus those on craniofacial and hand de-
velopment requires explanation, particularly since two
other mutants with comparable dominant negative ef-
fects are associated with the typical Char syndrome phe-
notype. One potential basis for this phenomenon would
depend on the expression patterns of TFAP2 coactiva-
tors. The PY motif has been shown to mediate inter-
actions between transcription factors and coactivators
(Yagi et al. 1999). Thus, adverse effects of P62R could
be more marked in certain tissues, in which coactivators
interacting with the PY motif play a greater role in
modulating transcriptional activation. Testing of this
hypothesis, particularly with respect to cardiovascular
development, must await identification of the relevant
TFAP2B coactivators.
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